BioArctic publishes the Annual Report for 2023

Stockholm April 18, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Annual Report for 2023 has been published.

The Annual Report, which is attached, can also be downloaded from the company’s website, www.bioarctic.se/en (Investors/Financial reports and presentations).

---

For further information, please contact:

Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Phone: +46 70 410 71 80 

This information is information that BioArctic AB (publ) is obliged to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication at 08:00 am CET on April 18, 2024.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovation of treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.